Author(s): LI Mei, XIE Chong, GUAN Yangtai, Department of Neurology, Changhai Hospital, Second Military Medical University, Department of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Pages: 24-28
Year: 2016 Issue:  1
Journal: Journal of Neurology and Neurorehabilitation
Keyword:  Multiple sclerosis; Induced pluripotent stem cells; Transdifferentiation;
Abstract: Multiple sclerosis(MS) is the most common inflammatory demyelinating disease of central nervous system and remains one of the major causes of disability in young adults. Conventional therapeutics can only prolong the remission duration, but do not cure it. Induced pluripotent stem cells(i PSCs) with the same totipotent differentiation as the stem cells have a broad prospect for application of cell replacement therapy in MS. Somatic cell reprogramming and transdifferentiating can shorten the time for generating oligodendrocyte cell lineage, as compared with the traditional method with i PSCs, which provides a new idea for the treatment of MS. With the improved efficiency and quality in obtaining neural stem cells and oligodendrocytes, it is possible to have a big achievement in cell therapy for MS.